We are live on ! Find out more
BMY icon

Bristol-Myers Squibb

2,214 hedge funds and large institutions have $100B invested in Bristol-Myers Squibb in 2020 Q3 according to their latest regulatory filings, with 136 funds opening new positions, 890 increasing their positions, 912 reducing their positions, and 91 closing their positions.

New
Increased
Maintained
Reduced
Closed

49% more first-time investments, than exits

New positions opened: 136 | Existing positions closed: 91

1% more funds holding

Funds holding: 2,1892,214 (+25)

1% more capital invested

Capital invested by funds: $98.8B → $100B (+$1.44B)

0.47% less ownership

Funds ownership: 74.52%74.06% (-0.47%)

2% less repeat investments, than reductions

Existing positions increased: 890 | Existing positions reduced: 912

9% less call options, than puts

Call options by funds: $1.25B | Put options by funds: $1.38B

15% less funds holding in top 10

Funds holding in top 10: 11093 (-17)

Holders
2,214
Holders Change
+25
Holders Change %
+1.14%
% of All Funds
44.67%
Holding in Top 10
93
Holding in Top 10 Change
-17
Holding in Top 10 Change %
-15.45%
% of All Funds
1.88%
New
136
Increased
890
Reduced
912
Closed
91
Calls
$1.25B
Puts
$1.38B
Net Calls
-$126M
Net Calls Change
+$11.2M
Name Holding Trade Value Shares
Change
Change in
Stake
CCMT
901
CMT Capital Markets Trading
Germany
$2.42M
HBT
902
Hills Bank & Trust
Iowa
$2.41M -$75.3K -1,251 -3%
VFM
903
Viking Fund Management
North Dakota
$2.41M -$1.5M -25,000 -38%
AAM
904
Advisors Asset Management
Colorado
$2.41M +$496K +8,244 +26%
MIM
905
Marco Investment Management
Georgia
$2.4M +$445K +7,400 +23%
VCM
906
Virtue Capital Management
Tennessee
$2.39M -$72.9K -1,212 -3%
Nomura Holdings
907
Nomura Holdings
Japan
$2.39M -$2.35M -39,098 -49%
MI
908
Markston International
New York
$2.39M -$49.5K -822 -2%
WAM
909
Wakefield Asset Management
Colorado
$2.39M -$12.2K -203 -0.5%
HDIM
910
Hanson & Doremus Investment Management
Vermont
$2.38M +$1.02K +17 +0%
TSWM
911
Triangle Securities Wealth Management
North Carolina
$2.38M -$24.7K -410 -1%
TRCT
912
Tower Research Capital (TRC)
New York
$2.38M +$762K +12,662 +47%
GIA
913
Gladstone Institutional Advisory
Florida
$2.37M -$22.9K -381 -1%
PPP
914
Private Portfolio Partners
New Jersey
$2.35M +$54.5K +906 +2%
YIA
915
YHB Investment Advisors
Connecticut
$2.33M -$1.92M -31,946 -45%
MYAM
916
Meiji Yasuda Asset Management
Japan
$2.33M -$1.09M -18,170 -32%
APF
917
Alaska Permanent Fund
Alaska
$2.33M +$1.14M +18,920 +96%
LCM
918
Logan Capital Management
Pennsylvania
$2.32M +$30.1K +500 +1%
SFO
919
Stokes Family Office
Louisiana
$2.32M +$50.3K +835 +2%
SIC
920
Sigma Investment Counselors
Michigan
$2.32M -$2.29M -38,084 -50%
MCM
921
Mitchell Capital Management
Kansas
$2.31M +$64.2K +1,067 +3%
LWS
922
Lucia Wealth Services
California
$2.31M +$389K +6,462 +20%
OC
923
Oarsman Capital
Wisconsin
$2.3M +$112K +1,855 +5%
KC
924
Knuff & Co
California
$2.3M -$247K -4,097 -10%
APP
925
Avantax Planning Partners
Iowa
$2.3M -$38.1K -633 -2%

BMY Hedge Fund Activity: Q3 2020 in Review

2,214 of the 4,956 institutional investors tracked by Wall St. Rank reported a position in Bristol-Myers Squibb (BMY) for Q3 2020, worth a combined $100B — up 1.5% from $98.8B a quarter earlier.

Buyers outnumbered sellers: 136 funds opened new BMY positions and 91 closed out — a net gain of 45 holders — while 890 added to existing stakes and 912 trimmed.

The largest buyer was Berkshire Hathaway, opening a new position worth an estimated $1.8B. The largest seller was Renaissance Technologies, cutting an estimated $778M.

  • 2,214 institutional investors held Bristol-Myers Squibb (BMY) as of Q3 2020, up from 2,189 in Q2 2020.
  • Funds reported $100B of Bristol-Myers Squibb stock for Q3 2020, up 1.5% quarter-over-quarter.
  • 136 funds opened new Bristol-Myers Squibb positions in Q3 2020 and 91 closed out, a net change of +45 holders.
  • The largest Bristol-Myers Squibb buyer in Q3 2020 was Berkshire Hathaway, an estimated $1.8B added.
  • The largest Bristol-Myers Squibb seller in Q3 2020 was Renaissance Technologies, an estimated $778M sold.

Based on aggregated 13F filings for Q3 2020.